These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25284324)

  • 21. Effective gene therapy in an authentic model of Tay-Sachs-related diseases.
    Cachón-González MB; Wang SZ; Lynch A; Ziegler R; Cheng SH; Cox TM
    Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10373-10378. PubMed ID: 16801539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuronal lysosomal enzyme replacement using fragment C of tetanus toxin.
    Dobrenis K; Joseph A; Rattazzi MC
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2297-301. PubMed ID: 1532255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic Gene Transfer of a Hexosaminidase Variant Using an scAAV9.47 Vector Corrects GM2 Gangliosidosis in Sandhoff Mice.
    Osmon KJ; Woodley E; Thompson P; Ong K; Karumuthil-Melethil S; Keimel JG; Mark BL; Mahuran D; Gray SJ; Walia JS
    Hum Gene Ther; 2016 Jul; 27(7):497-508. PubMed ID: 27199088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Biomarkers of Human GM1 Gangliosidosis Reflect the Clinical Efficacy of Gene Therapy in a Feline Model.
    Gray-Edwards HL; Regier DS; Shirley JL; Randle AN; Salibi N; Thomas SE; Latour YL; Johnston J; Golas G; Maguire AS; Taylor AR; Sorjonen DC; McCurdy VJ; Christopherson PW; Bradbury AM; Beyers RJ; Johnson AK; Brunson BL; Cox NR; Baker HJ; Denney TS; Sena-Esteves M; Tifft CJ; Martin DR
    Mol Ther; 2017 Apr; 25(4):892-903. PubMed ID: 28236574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural history study of glycan accumulation in large animal models of GM2 gangliosidoses.
    Cavender C; Mangini L; Van Vleet JL; Corado C; McCullagh E; Gray-Edwards HL; Martin DR; Crawford BE; Lawrence R
    PLoS One; 2020; 15(12):e0243006. PubMed ID: 33259552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates.
    Walia JS; Altaleb N; Bello A; Kruck C; LaFave MC; Varshney GK; Burgess SM; Chowdhury B; Hurlbut D; Hemming R; Kobinger GP; Triggs-Raine B
    Mol Ther; 2015 Mar; 23(3):414-22. PubMed ID: 25515709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice.
    Itakura T; Kuroki A; Ishibashi Y; Tsuji D; Kawashita E; Higashine Y; Sakuraba H; Yamanaka S; Itoh K
    Biol Pharm Bull; 2006 Aug; 29(8):1564-9. PubMed ID: 16880605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canine GM2-Gangliosidosis Sandhoff Disease Associated with a 3-Base Pair Deletion in the HEXB Gene.
    Wang P; Henthorn PS; Galban E; Lin G; Takedai T; Casal M
    J Vet Intern Med; 2018 Jan; 32(1):340-347. PubMed ID: 29106755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigating Immune Responses to the scAAV9-
    Kot S; Karumuthil-Melethil S; Woodley E; Zaric V; Thompson P; Chen Z; Lykken E; Keimel JG; Kaemmerer WF; Gray SJ; Walia JS
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recent advances in molecular genetics of GM2 gangliosidosis].
    Wakamatsu N
    Nihon Rinsho; 1995 Dec; 53(12):2988-93. PubMed ID: 8577047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease.
    Kodama T; Togawa T; Tsukimura T; Kawashima I; Matsuoka K; Kitakaze K; Tsuji D; Itoh K; Ishida Y; Suzuki M; Suzuki T; Sakuraba H
    PLoS One; 2011; 6(12):e29074. PubMed ID: 22205997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel bicistronic lentiviral vectors correct β-Hexosaminidase deficiency in neural and hematopoietic stem cells and progeny: implications for in vivo and ex vivo gene therapy of GM2 gangliosidosis.
    Ornaghi F; Sala D; Tedeschi F; Maffia MC; Bazzucchi M; Morena F; Valsecchi M; Aureli M; Martino S; Gritti A
    Neurobiol Dis; 2020 Feb; 134():104667. PubMed ID: 31682993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.
    Karumuthil-Melethil S; Nagabhushan Kalburgi S; Thompson P; Tropak M; Kaytor MD; Keimel JG; Mark BL; Mahuran D; Walia JS; Gray SJ
    Hum Gene Ther; 2016 Jul; 27(7):509-21. PubMed ID: 27197548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adeno-Associated Virus Gene Therapy in a Sheep Model of Tay-Sachs Disease.
    Gray-Edwards HL; Randle AN; Maitland SA; Benatti HR; Hubbard SM; Canning PF; Vogel MB; Brunson BL; Hwang M; Ellis LE; Bradbury AM; Gentry AS; Taylor AR; Wooldridge AA; Wilhite DR; Winter RL; Whitlock BK; Johnson JA; Holland M; Salibi N; Beyers RJ; Sartin JL; Denney TS; Cox NR; Sena-Esteves M; Martin DR
    Hum Gene Ther; 2018 Mar; 29(3):312-326. PubMed ID: 28922945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis.
    Sango K; McDonald MP; Crawley JN; Mack ML; Tifft CJ; Skop E; Starr CM; Hoffmann A; Sandhoff K; Suzuki K; Proia RL
    Nat Genet; 1996 Nov; 14(3):348-52. PubMed ID: 8896570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laboratory diagnosis of canine GM2-gangliosidosis using blood and cerebrospinal fluid.
    Yamato O; Satoh H; Matsuki N; Ono K; Yamasaki M; Maede Y
    J Vet Diagn Invest; 2004 Jan; 16(1):39-44. PubMed ID: 14974845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, Imaging, Genetic, and Disease Course Characteristics in Patients With GM2 Gangliosidosis: Beyond Age of Onset.
    Kern J; Böhringer J; Timmann D; Trollmann R; Stendel C; Kamm C; Röbl M; Santhanakumaran V; Groeschel S; Beck-Wödl S; Göricke S; Krägeloh-Mann I; Synofzik M
    Neurology; 2024 Jan; 102(1):e207898. PubMed ID: 38165373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adeno-associated virus-mediated expression of β-hexosaminidase prevents neuronal loss in the Sandhoff mouse brain.
    Sargeant TJ; Wang S; Bradley J; Smith NJ; Raha AA; McNair R; Ziegler RJ; Cheng SH; Cox TM; Cachón-González MB
    Hum Mol Genet; 2011 Nov; 20(22):4371-80. PubMed ID: 21852247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study.
    Nestrasil I; Ahmed A; Utz JM; Rudser K; Whitley CB; Jarnes-Utz JR
    Mol Genet Metab; 2018 Feb; 123(2):97-104. PubMed ID: 29352662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic correction in microglia derived from Sandhoff disease model mice.
    Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Itoh K
    J Neurochem; 2005 Sep; 94(6):1631-8. PubMed ID: 16092933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.